Disclosures

Editorial Board Member: Dr Andrew Gennery

Watson Reader/Honorary Consultant in Paediatric Immunology & Haematopoeitic Stem Cell Transplantation. Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK.

Disclosures: Dr Gennery has delivered lectures as part of an ‘in- house’ education staff to GSK Staff – Haematopoietic Stem Cell Transplantation for Primary Immunodeficiencies

Editorial Board member: Dr Robbert Bredius

MD PhD, Paediatric Immunologist – Infectious Disease – Stem Cell Transplant Dr. Department of Paediatrics, Immunology section, Hematology and Stem Cell Transplantation, Leiden University Medical Centre, The Netherlands.

Disclosures: Dr Bredius has delivered industry symposia presentations funded by GSK

Editorial Board member: Dr Fabio Candotti

MD PhD, Pediatrics, Pediatric Allergy and Immunology
Associate Professor of Medicine and Head Physician, Division of Immunology and Allergy
Director, Vaccine and Immunotherapy Center, University Hospital of Lausanne, Switzerland

Disclosures: Dr Candotti has no conflicts of interest to declare.

Expert Interviewee: Professor Marina Cavazzana

Head of the Biotherapy Department, Necker Chidren’s Hospital, Assistance Publique-Hôpitaux de Paris, France

Disclosures: Professor Cavazzana stated that she has no relationships to disclose

Expert Interviewee: Professor Eyal Grunebaum

Director of Paediatric Clinical Immunology & Allergy Residency Program; Head of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario, Canada

Disclosures:Professor Grunebaum stated that he has no relationships to disclose

Expert Interviewee: Professor Michael Hershfield

Professor of Medicine; Professor of Biochemistry, Duke University School of Medicine, Durham, NC, USA

Disclosures: Leadiant BioSciences: Grant Support and consulting related to monitoring treatment of ADA deficiency with PEGylated ADA; Orchard Therapeutics: Peforming laboratory testing of samples of patients involved in trial at Great Ormond Street Hospital of gene therapy for ADA deficiency (unfunded)

Share This: